Home Biosimilar Antibodies Immunology & Inflammation PD-1/PD-L1 Cosibelimab (Anti-B7-H1 / PD-L1 / CD274)
For research use only. Not for use in humans.

Cosibelimab (Anti-B7-H1 / PD-L1 / CD274)

Synonyms: PD-L1， B7-H1

Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD.

Cosibelimab (Anti-B7-H1 / PD-L1 / CD274)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 14
BMS-1 13
BMS-202 28
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 5
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD.
References

Product Details

CAS No. 2216751-26-5
Molecular Weight 144.64
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07049926 RECRUITING Drug: Belzutifan|Drug: Zanzalintinib Renal Cell Carcinoma Merck Sharp & Dohme LLC 2025-07-20 PHASE1; PHASE2
NCT06898957 ACTIVE_NOT_RECRUITING Drug: YL201|Drug: Tarlatamab|Drug: Durvalumab Small Cell Lung Cancer Amgen 2025-05-16 PHASE1
NCT07426484 RECRUITING Drug: Cosibelimab|Drug: Prednisone|Drug: Sirolimus|Drug: Eve Cutaneous Squamous Cell Carcinoma; Skin Cancer Dana-Farber Cancer Institute 2026-04-23 PHASE4
NCT04929041 ACTIVE_NOT_RECRUITING Lung Adenocarcinoma; Lung Adenosquamous Carcinoma; Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 National Cancer Institute (NCI) 2022-10-07 PHASE2; PHASE3
NCT07001618 RECRUITING Drug: MaaT033 capsule|Drug: Cemiplimab|Drug: Cisplatin|Drug: NSCLC (Advanced Non-small Cell Lung Cancer) Gustave Roussy, Cancer Campus, Grand Paris 2025-11-17 PHASE2
NCT06731413 RECRUITING Drug: Reduced Dose of Chemotherapy and Immunotherapy Non-Small Cell Lung Cancer; NSCLC; Advanced Non-Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer Virginia Commonwealth University 2025-02-11 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.